Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

PaperCitations, authors & open-access status

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 68 citations, 2019 year and bronze oa status.

68
Citations
2019
Year
bronze
OA Status

Related on ScholarIQ

C. Zhou
Author
Annals of Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Brain Metastases and Treatment
Topic
Lung Cancer Research Studies
Topic
470M+ articles · free account